Drugs / Pomalidomide
Pomalidomide
also known as
CC-4047 · POM · Pomalyst · Imnovid · Actimid · IMID 3 · Imnovid (previously pomalidomide celgene) · Pomalidomida · +7 more
Other / unclassified targets TNF via inhibition
Regulatory milestones approvals, filings & regulatory actions · 5 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | POMALYST | — | 2015-04-23 – 2020-11-20 | fda.gov ↗ |
| Approved | EU (EMA) | Imnovid (previously Pomalidomide Celgene) | — | 2013-08-05 | europa.eu ↗ |
| Approved | US (FDA) | POMALYST | — | 2013-02-08 | fda.gov ↗ |
Trials 205 · started per year
today
US approved 2013
EU approved 2013
1
5
4
3
6
9
16
10
18
10
9
11
6
9
8
19
22
10
9
8
9
20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 150 trials · 1 met primary | ||||||
| Phase 1 | NCT07831122 | Dec 2026 → Jan 2033 expected | refractory plasma cell neoplasm | Canadian Myeloma Research Group | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07532525 | Sep 2026 → Oct 2027 expected | B-cell acute lymphoblastic leukemia, precursor B-cell acute lymphoblastic leukemia | University of Michigan Rogel Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06768489 | Dec 2024 → Jan 2029 expected | AL amyloidosis, smoldering plasma cell myeloma | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT05389423 | Jun 2023 → Jun 2028 expected | Burkitt lymphoma, plasmablastic lymphoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT05651932 | Feb 2023 → Dec 2027 expected | plasma cell myeloma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05556616 | Jan 2023 → Jun 2024 | plasma cell myeloma | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05556798 | Oct 2022 → Oct 2026 expected | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05137054 | Aug 2022 → Mar 2028 expected | plasma cell myeloma | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT04895410 | Jan → Jun 2022 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04902443 | Dec 2021 → Dec 2026 expected | Kaposi's sarcoma, lymphoid neoplasm | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT04667663 | Dec 2021 → Apr 2022 overdue | plasma cell myeloma | Cancer Trials Ireland | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05050097 | Sep 2021 → Mar 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04392648 | Jun 2020 → Nov 2023 | refractory plasma cell neoplasm | Teva Branded Pharmaceutical Products R&D, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04108195 | Feb 2020 → Apr 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03828292 | Mar 2019 → Apr 2023 | plasma cell myeloma | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT03798314 | Jan 2019 → Dec 2020 | central nervous system non-hodgkin lymphoma, primary vitreoretinal large b-cell lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT03582033 | Nov 2018 → Nov 2023 | plasma cell myeloma | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03269136 | Nov 2017 → Jan 2024 | plasma cell myeloma | Pfizer | Completed | Met primary |
| Phase 1 | NCT03287908 | Nov 2017 → Jun 2023 | refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03015922 | Jun 2017 → Sep 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 1 | NCT03023527 | Jan 2017 → Jan 2018 | plasma cell myeloma | PETHEMA Foundation | Terminated | No outcome recorded |
| Phase 1 | NCT02900716 | Sep 2016 → Nov 2020 | B-cell chronic lymphocytic leukemia | Zhejiang DTRM Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT02659930 | Jan 2016 → Jan 2028 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02616640 | Jan 2016 → Nov 2018 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02431208 | Jul 2015 → Mar 2021 | plasma cell myeloma | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02415153 | Jul 2015 → Jul 2019 | childhood brain stem glioma, neurofibromatosis type 1, optic pathway glioma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02283775 | May 2015 → May 2021 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02287558 | Jan 2015 → Jun 2019 | hereditary hemorrhagic telangiectasia | The Cleveland Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02189343 | Sep 2014 → Apr 2018 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01999335 | Jul 2014 → Apr 2019 | plasma cell myeloma | Amgen | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01889420 | Jul 2014 → Jun 2015 | plasma cell myeloma | New Mexico Cancer Research Alliance | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02103335 | Jun 2014 → Oct 2016 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02168205 | May → Sep 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02071888 | Feb 2014 → Apr 2016 | T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, plasma cell myeloma | Calithera Biosciences, Inc | Completed | No outcome recorded |
| Phase 1 | NCT01807286 | Jan 2014 → Feb 2016 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02029950 | Dec 2013 → May 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01986894 | Oct → Dec 2013 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01722305 | Apr 2013 → Jun 2016 | diffuse large B-cell lymphoma of the central nervous system, intraocular lymphoma, retina lymphoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01835561 | Mar 2013 → Aug 2014 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01728259 | Mar 2013 → Oct 2018 | light chain deposition disease, primary systemic amyloidosis | Barbara Ann Karmanos Cancer Institute | Terminated | No outcome recorded |
| Phase 1 | NCT01707407 | Sep → Nov 2012 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01575925 | Jun 2012 → Aug 2018 | impaired renal function disease, plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01562405 | May 2012 → Dec 2026 expected | plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01568294 | Apr 2012 → Jul 2015 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01497093 | Feb 2012 → Jul 2019 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01474330 | Aug → Oct 2011 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01198067 | Oct 2010 → May 2025 | Waldenstrom macroglobulinemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT01078974 | May 2010 → Sep 2015 | Waldenstrom macroglobulinemia | Steven P. Treon, MD, PhD | Terminated | No outcome recorded |
| Phase 1 | NCT01522547 | Aug 2007 → Oct 2012 | sickle cell disease | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00482521 | Mar 2007 → Sep 2010 | cancer of unknown primary site | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1/232 trials · 4 met primary | ||||||
| Phase 1/2 | NCT07463807 | Jul → Aug 2026 overdue | plasma cell myeloma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07441954 | Mar 2026 → Dec 2027 expected | indolent B-cell non-Hodgkin lymphoma | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06855823 | Jan 2025 → Dec 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06554561 | Aug 2024 → Aug 2026 overdue | primary central nervous system lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06246162 | Nov 2023 → Nov 2025 overdue | plasma cell myeloma | Affiliated Hospital of Nantong University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05408026 | Oct 2022 → Oct 2025 | refractory plasma cell neoplasm | Alliance Foundation Trials, LLC. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04973605 | Sep 2021 → Nov 2026 expected | refractory plasma cell neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04762745 | Feb 2021 → Feb 2022 | plasma cell myeloma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02542657 | Oct 2015 → Aug 2025 overdue | plasma cell myeloma | Joseph Tuscano | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02343042 | Oct 2015 → Apr 2027 expected | plasma cell myeloma | Karyopharm Therapeutics Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02384083 | Sep 2015 → Feb 2018 | plasma cell myeloma | PETHEMA Foundation | Completed | Met primary |
| Phase 1/2 | NCT02289222 | Dec 2014 → Aug 2017 | plasma cell myeloma | Ashraf Badros | Terminated | No outcome recorded |
| Phase 1/2 | NCT01946152 | Mar 2014 → Mar 2020 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02004275 | Feb 2014 → Dec 2021 | plasma cell myeloma | Alliance for Clinical Trials in Oncology | Unknown | Met primary |
| Phase 1/2 | NCT01979276 | Nov 2013 → Oct 2016 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01644110 | Aug 2013 → Apr 2024 | myelofibrosis, myelofibrosis with myeloid metaplasia | University of Ulm | Completed | No outcome recorded |
| Phase 1/2 | NCT01754402 | Jan 2013 → Dec 2016 | plasma cell myeloma | Cristina Gasparetto | Unknown | No outcome recorded |
| Phase 1/2 | NCT01592370 | Aug 2012 → Sep 2020 | Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT01570387 | Jun 2012 → Nov 2018 | AL amyloidosis | Boston Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01522872 | Feb 2012 → Sep 2016 | plasma cell myeloma | Threshold Pharmaceuticals | Unknown | No outcome recorded |
| Phase 1/2 | NCT01541332 | Feb 2012 → Dec 2016 | plasma cell myeloma | Oncotherapeutics | Unknown | No outcome recorded |
| Phase 1/2 | NCT01495598 | Jan 2012 → May 2022 | Kaposi's sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01464034 | Nov 2011 → Jul 2020 | plasma cell myeloma | Criterium, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01432600 | Nov 2011 → Aug 2016 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | Met primary |
| Phase 1/2 | NCT01212952 | Sep 2011 → Aug 2017 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT01421186 | Jul 2011 → Aug 2020 | plasma cell myeloma | MorphoSys AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01166113 | Jul 2010 → Jun 2011 | plasma cell myeloma | Fondazione EMN Italy Onlus | Completed | No outcome recorded |
| Phase 1/2 | NCT00833833 | Jun 2008 → Apr 2011 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 1/2 | NCT00669578 | May 2008 → Jul 2010 | myelofibrosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT00537511 | Feb 2008 → Nov 2010 | small cell carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT00540579 | Nov 2007 → Dec 2008 | malignant pancreatic neoplasm | SCRI Development Innovations, LLC | Completed | No outcome recorded |
| Phase 289 trials · 2 met primary · 2 missed | ||||||
| Phase 2 | NCT07825064 | Oct 2026 → Apr 2029 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 2 | NCT07560449 | Jun 2026 → Jun 2028 expected | plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227311 | Apr 2026 → Aug 2030 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT07523737 | Apr 2026 → Mar 2028 expected | diffuse large B-cell lymphoma, primary central nervous system lymphoma | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07018050 | Sep 2025 → Nov 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07312188 | Jul 2025 → May 2028 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 2 | NCT05922501 | May 2024 → Dec 2028 expected | plasma cell myeloma | Massachusetts General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06342466 | May 2024 → Dec 2026 expected | AL amyloidosis | Jin Lu, MD | Recruiting | No outcome recorded |
| Phase 2 | NCT05911321 | Dec 2023 → Jun 2025 overdue | plasma cell myeloma, refractory plasma cell neoplasm | UNC Lineberger Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06158412 | Nov 2023 → Dec 2025 overdue | plasma cell myeloma | The First Affiliated Hospital of Xiamen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05789303 | May 2023 → Jul 2028 expected | plasma cell myeloma | University of Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT05432414 | Dec 2022 → Dec 2023 | plasma cell myeloma | RenJi Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05931328 | Oct 2022 → Oct 2024 overdue | primary central nervous system lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT05478993 | Oct 2022 → Jul 2024 | plasma cell myeloma | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04802161 | Aug 2022 → Nov 2024 overdue | acute myeloid leukemia with multilineage dysplasia, chronic myelomonocytic leukemia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05208307 | Jul 2022 → Oct 2027 expected | plasma cell myeloma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT05288062 | Jun 2022 → Feb 2024 | smoldering plasma cell myeloma | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT06255847 | Jun 2022 → Jun 2025 | plasma cell myeloma | Shanxi Bethune Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04850599 | Jun 2022 → Oct 2027 expected | plasma cell myeloma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05348213 | May 2022 → Jun 2025 overdue | diffuse large B-cell lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05390749 | Apr 2022 → Apr 2024 | primary central nervous system lymphoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04577755 | Mar 2022 → Feb 2027 expected | Kaposi's sarcoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04941937 | Jan 2022 → Dec 2025 | plasma cell myeloma | Juan Du | Unknown | No outcome recorded |
| Phase 2 | NCT04835129 | Jan 2022 → Apr 2027 expected | plasma cell myeloma | Medical College of Wisconsin | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04843579 | Dec 2021 → Nov 2022 | plasma cell myeloma | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04925193 | Nov 2021 → Aug 2024 overdue | plasma cell myeloma | University of Colorado, Denver | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04892446 | Nov 2021 → Apr 2024 | plasma cell myeloma | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT04302324 | Oct 2021 → May 2024 overdue | plasma cell myeloma, refractory plasma cell neoplasm | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05509374 | Oct 2021 → Jun 2024 | plasma cell myeloma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04883242 | Jul 2021 → Dec 2026 expected | plasma cell myeloma | University of Washington | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04895917 | Jun 2021 → Dec 2024 | AL amyloidosis | Fondazione IRCCS Policlinico San Matteo di Pavia | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03601806 | Apr 2021 → Nov 2024 | HIV infectious disease, Kaposi's sarcoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT04270175 | Apr 2021 → Jan 2027 expected | AL amyloidosis | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04584307 | Apr 2021 → Dec 2023 | plasma cell myeloma | Natalie Callendar | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04661137 | Mar 2021 → Feb 2028 expected | plasma cell myeloma | Hackensack Meridian Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04508790 | Nov 2020 → Feb 2027 expected | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04287855 | Aug 2020 → Apr 2025 | plasma cell myeloma | Poitiers University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04191616 | Aug 2020 → Nov 2022 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT03959358 | Jul 2020 → Jun 2022 | amyloidosis, plasma cell myeloma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 2 | NCT04305444 | Apr 2020 → Dec 2024 | B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma | Zhejiang DTRM Biopharma | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03683277 | Nov 2019 → Dec 2022 | disease of genetic or genomic mechanism, plasma cell myeloma, refractory plasma cell neoplasm | Intergroupe Francophone du Myelome | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03910244 | Oct 2019 → Sep 2023 | hereditary hemorrhagic telangiectasia | The Cleveland Clinic | Completed | Met primary |
| Phase 2 | NCT04124497 | Jul 2019 → Jul 2027 expected | chromosome 17p deletion, plasma cell myeloma | Fondazione EMN Italy Onlus | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03756896 | Jan 2019 → Jun 2025 overdue | plasma cell myeloma | Emory University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03713294 | Jan 2019 → Feb 2024 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03227432 | Dec 2018 → Dec 2021 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03590652 | Oct 2018 → Jul 2025 | refractory plasma cell neoplasm | University of California, San Diego | Terminated | No outcome recorded |
| Phase 2 | NCT03520985 | Oct 2018 → Feb 2021 | refractory plasma cell neoplasm | Swiss Cancer Institute | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03731832 | Sep 2018 → Apr 2024 | plasma cell myeloma | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03601624 | Sep → Dec 2018 | plasma cell myeloma | Institute for Social Security and Services for State Workers | Unknown | No outcome recorded |
| Phase 2 | NCT03030261 | Nov 2017 → Sep 2022 overdue | plasma cell myeloma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03215524 | Oct 2017 → Jun 2022 | plasma cell myeloma | Canadian Myeloma Research Group | Completed | No outcome recorded |
| Phase 2 | NCT03257631 | Sep 2017 → Sep 2023 | medulloblastoma | Celgene Corporation | Completed | Missed primary |
| Phase 2 | NCT03202628 | Jul 2017 → Apr 2021 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT03113942 | Jun 2017 → Mar 2019 | squamous cell intraepithelial neoplasia | Kirby Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03104270 | Mar 2017 → Oct 2019 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04243109 | Feb 2017 → May 2019 | plasma cell myeloma | Maimónides Biomedical Research Institute of Córdoba | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02807454 | Jul 2016 → Jan 2022 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT02718833 | Jun 2016 → Dec 2026 expected | plasma cell myeloma | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02406222 | Mar 2016 → Dec 2022 overdue | plasma cell myeloma | University of Leeds | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02612779 | Feb 2016 → Jul 2019 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02547662 | Dec 2015 → Oct 2020 | plasma cell leukemia, plasma cell myeloma, plasmacytoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02578121 | Dec 2015 → Jan 2017 | plasma cell myeloma | University of Arkansas | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03242460 | May 2015 → Apr 2019 | refractory plasma cell neoplasm | Kosin University Gospel Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02158702 | Nov 2014 → Feb 2018 | plasma cell myeloma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT02188368 | Jul 2014 → Oct 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02176213 | Jun 2014 → May 2019 | plasma cell myeloma | Ajai Chari | Completed | No outcome recorded |
| Phase 2 | NCT01946477 | May 2014 → Apr 2025 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02244125 | Apr 2014 → Jan 2017 | plasma cell myeloma | Institut Curie | Completed | No outcome recorded |
| Phase 2 | NCT02046915 | Apr 2014 → Aug 2016 | refractory plasma cell neoplasm | University Hospital Tuebingen | Completed | No outcome recorded |
| Phase 2 | NCT01794039 | Mar 2014 → Nov 2016 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02045017 | Feb 2014 → Jan 2017 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02011113 | Dec 2013 → Sep 2014 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 2 | NCT01745588 | Dec 2012 → Sep 2025 | plasma cell myeloma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01688466 | Aug 2012 → Mar 2017 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01559129 | Aug 2012 → Nov 2016 | interstitial lung disease, systemic sclerosis | Celgene Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01510613 | Feb 2012 → Dec 2016 | AL amyloidosis | Fondazione IRCCS Policlinico San Matteo di Pavia | Completed | No outcome recorded |
| Phase 2 | NCT01745640 | Jan 2012 → Dec 2015 | plasma cell myeloma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2 | NCT01177735 | Oct 2011 → Sep 2013 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT01319422 | Jun 2011 → Nov 2014 | plasma cell myeloma | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01159574 | Aug 2010 → May 2015 | plasma cell myeloma | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 2 | NCT01135199 | Apr → Jun 2010 | pulmonary fibrosis | Stanford University | Withdrawn | No outcome recorded |
| Phase 2 | NCT00949364 | Dec 2009 → Dec 2016 | myeloproliferative neoplasm | University of Ulm | Completed | No outcome recorded |
| Phase 2 | NCT00946270 | Jul 2009 → May 2018 | acquired polycythemia vera, thrombocytosis disease | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00770757 | Feb 2009 → Oct 2010 | graft versus host disease | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00717522 | Aug 2008 → Jan 2009 | soft tissue sarcoma | Celgene Corporation | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00558896 | Nov 2007 → Sep 2012 | plasma cell myeloma | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT00463385 | Apr 2007 → May 2009 | myelofibrosis, myelofibrosis with myeloid metaplasia | Celgene Corporation | Completed | Missed primary |
| Phase 2 | NCT00072722 | Sep 2003 → Apr 2005 | prostate cancer | Celgene Corporation | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06879379 | Mar 2025 → Mar 2028 expected | plasma cell myeloma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 318 trials · 7 met primary · 1 missed | ||||||
| Phase 3 | NCT07222761 | Jan 2026 → May 2029 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT07138209 | Nov 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06158841 | May 2024 → Dec 2027 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT06208150 | Jan 2024 → Apr 2026 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05572515 | Mar 2023 → Oct 2025 overdue | refractory plasma cell neoplasm | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT05455320 | Oct 2022 → Jul 2027 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT05519085 | Sep 2022 → Jan 2027 expected | refractory plasma cell neoplasm | Celgene Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT05083169 | Oct 2021 → Aug 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT05236621 | Jan 2021 → Jun 2022 | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04181827 | Jun 2020 → May 2024 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | Met primary |
| Phase 3 | NCT03651128 | Apr 2019 → Apr 2026 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT02916420 | Sep 2016 → Jun 2018 | plasma cell myeloma | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03440411 | Feb 2016 → Dec 2019 | plasma cell myeloma | Fondazione EMN Italy Onlus | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01734928 | Jan 2013 → May 2022 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT01712789 | Nov 2012 → Dec 2019 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01311687 | Mar 2011 → Mar 2013 | plasma cell myeloma | Celgene Corporation | Completed | Met primary |
| Phase 3 | NCT01324947 | Mar 2011 → Jul 2014 | plasma cell myeloma | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01178281 | Sep 2010 → Jan 2013 | myelofibrosis, primary myelofibrosis | Celgene Corporation | Completed | Missed primary |
| Phase 43 trials | ||||||
| Phase 4 | NCT05555329 | Dec 2022 → Feb 2024 | plasma cell myeloma | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 4 | NCT05183139 | Jun 2022 → Dec 2026 | plasma cell myeloma | Takeda | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04989140 | Jul 2021 → Jul 2024 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07257510 | Aug 2025 → Aug 2028 expected | mantle cell lymphoma | Peking University Third Hospital | Recruiting | No outcome recorded |
| — | NCT07015021 | Jun 2025 → Sep 2026 overdue | plasma cell myeloma | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| — | NCT06924424 | Mar 2025 → Dec 2026 expected | plasma cell myeloma | Peking University People's Hospital | Active not recruiting | No outcome recorded |
| — | NCT07072208 | Nov 2024 → May 2027 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| — | NCT06832228 | Sep 2024 → Sep 2025 overdue | diffuse large B-cell lymphoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT06455748 | Mar 2024 → Jan 2025 | AL amyloidosis | Yongyong MA | Unknown | No outcome recorded |
| — | NCT05809180 | Jan 2023 → Jul 2025 | diffuse large B-cell lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| — | NCT06376214 | Jan 2023 → Dec 2025 overdue | AL amyloidosis | Nanjing University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05378971 | May 2022 → May 2025 | plasma cell myeloma | LanZhou University | Unknown | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT03723096 | — | plasma cell myeloma | Celgene Corporation | No longer available | No outcome recorded |
| — | NCT03763370 | — | plasma cell myeloma | GlaxoSmithKline | Available | No outcome recorded |
| — | NCT01632826 | — | plasma cell myeloma | Celgene Corporation | Approved for marketing | No outcome recorded |
| Comparator or background therapy86 trials | ||||||
| Phase 0 | NCT01537861 Background | Jun 2012 → Feb 2014 | plasma cell myeloma | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1 | NCT05828459 Background | Jul 2023 → Jan 2027 expected | cancer, hematopoietic and lymphoid cell neoplasm | Onward Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05259839 Background | Oct 2022 → Sep 2033 expected | refractory plasma cell neoplasm | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04910568 Background | Jul 2021 → Dec 2028 expected | plasma cell myeloma | Genentech, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04355039 Background | Jul 2021 → Jul 2023 | refractory plasma cell neoplasm | Medical College of Wisconsin | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT04722146 Background | Mar 2021 → Oct 2025 overdue | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04045795 Background | Aug 2019 → Mar 2024 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT03984097 Background | Jul 2019 → Mar 2026 | plasma cell myeloma | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03657420 Background | May 2019 → Sep 2021 | plasma cell myeloma | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03143985 Background | Jul 2017 → Feb 2022 | plasma cell myeloma | Koen van Besien | Completed | No outcome recorded |
| Phase 1 | NCT02939183 Background | Jan 2017 → Oct 2022 | refractory plasma cell neoplasm | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02569320 Background | May 2016 → Nov 2020 | plasma cell myeloma | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT02400242 Background | May 2015 → Jun 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT02462525 Background | May 2015 → Dec 2017 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 1 | NCT01998971 Background | Feb 2014 → Jan 2019 | plasma cell myeloma | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1/2 | NCT06953960 Comparator | Jul 2025 → Dec 2030 expected | plasma cell myeloma | AbbVie | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06660498 Comparator | May 2025 → Mar 2027 expected | HIV infectious disease | University of Aarhus | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06106945 Background | Dec 2023 → Aug 2027 expected | plasma cell myeloma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05714839 Background | Jun 2023 → Aug 2028 expected | plasma cell myeloma | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05451771 Comparator | Oct 2022 → Sep 2027 expected | AL amyloidosis | Columbia University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05581875 Background | Oct 2022 → Oct 2026 expected | corneal disorder, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07150104 Background | Aug 2022 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04942067 Background | Dec 2021 → Sep 2024 | amyloidosis, plasma cell myeloma | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05205252 Comparator | Dec 2021 → Jul 2023 | refractory hematologic cancer | Epizyme, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04764942 Background | May 2021 → May 2026 overdue | plasma cell myeloma | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04643002 Comparator | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04150965 Background | Jul 2020 → Aug 2024 | plasma cell myeloma, refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Terminated | No outcome recorded |
| Phase 1/2 | NCT04094961 Background | Sep 2019 → Jun 2025 overdue | plasma cell myeloma | Omar Nadeem, MD | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03732703 Background | Apr 2019 → Dec 2024 | refractory plasma cell neoplasm | Multiple Myeloma Research Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT03715478 Background | Nov 2018 → Jun 2025 overdue | refractory plasma cell neoplasm | Canadian Myeloma Research Group | Active not recruiting | Met primary |
| Phase 1/2 | NCT03439280 Background | Apr 2018 → Jan 2022 | plasma cell myeloma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02548962 Background | Mar 2016 → Jun 2018 | plasma cell myeloma | Pharmacyclics LLC. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02206425 Background | Sep 2014 → Jan 2018 | plasma cell myeloma | Oncotherapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT02228512 Comparator | Aug 2014 → May 2015 | large B-cell lymphoma, primary effusion lymphoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02119468 Background | Jun 2014 → May 2016 | plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT02185820 Background | Jun 2014 → Jul 2015 | plasma cell myeloma | European Myeloma Network B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT01997840 Background | Mar 2014 → Feb 2024 | plasma cell myeloma | Celgene Corporation | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT01665794 Background | Aug 2012 → Nov 2025 | plasma cell myeloma | University of Chicago | Completed | Met primary |
| Phase 2 | NCT06948084 Comparator | May 2027 → Feb 2028 expected | plasma cell myeloma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT07096778 Background | Jan 2026 → Dec 2029 expected | plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06594432 Background | Oct 2024 → Dec 2026 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05050305 Background | Mar 2024 → Dec 2025 | plasma cell myeloma | Dana-Farber Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT05669989 Background | Apr 2023 → Nov 2026 expected | plasma cell myeloma | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04700176 Background | May 2022 → Nov 2023 | plasma cell myeloma | Hackensack Meridian Health | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05298683 Background | May 2022 → Nov 2025 | impaired renal function disease, monoclonal paraproteinemia disease, plasma cell myeloma | Hellenic Society of Hematology | Unknown | No outcome recorded |
| Phase 2 | NCT05066607 Background | Feb 2022 → Mar 2026 | AL amyloidosis | Intergroupe Francophone du Myelome | Unknown | No outcome recorded |
| Phase 2 | NCT04790474 Background | Mar 2021 → Mar 2026 overdue | plasma cell myeloma | Tel-Aviv Sourasky Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03841565 Background | Aug 2020 → Feb 2022 | plasma cell myeloma | Academic and Community Cancer Research United | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT04176718 Background | May 2020 → May 2027 expected | plasma cell myeloma | Andrew Yee, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03567616 Background | Oct 2018 → Jun 2020 | plasma cell myeloma | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT03170882 Comparator | Aug 2017 → Aug 2020 | refractory plasma cell neoplasm | Millennium Pharmaceuticals, Inc. | Completed | Missed primary |
| Phase 2 | NCT02719613 Background | Jul 2016 → Feb 2026 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT02654132 Background | Mar 2016 → Jan 2018 | plasma cell myeloma | Bristol-Myers Squibb | Completed | Met primary |
| Phase 2 | NCT02294357 Background | Dec 2014 → Sep 2020 | plasma cell myeloma | Oncotherapeutics | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01053949 Comparator | Oct 2009 → Apr 2014 | plasma cell myeloma | University Hospital, Lille | Completed | No outcome recorded |
| Phase 3 | NCT07555938 Background | Jun 2026 → Oct 2028 expected | plasma cell myeloma | Hoffmann-La Roche | Recruiting | No outcome recorded |
| Phase 3 | NCT07623798 Comparator | Jun 2026 → May 2029 expected | refractory plasma cell neoplasm | Innovent Biologics (Suzhou) Co. Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07569757 Comparator | Jun 2026 → Dec 2028 expected | plasma cell myeloma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07452198 Comparator | Mar 2026 → Mar 2029 expected | plasma cell myeloma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07391657 Comparator | Feb 2026 → Jun 2028 expected | refractory plasma cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT07579234 Comparator | Jan 2026 → Jan 2029 expected | refractory plasma cell neoplasm | Shandong New Time Pharmaceutical Co., LTD | Recruiting | No outcome recorded |
| Phase 3 | NCT06615479 Background | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 3 | NCT06742138 Background | Jan 2025 → Dec 2027 expected | plasma cell myeloma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06413498 Comparator | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06508983 Background | Jun 2024 → Mar 2027 expected | refractory plasma cell neoplasm | Hangzhou Sumgen Biotech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06232707 Comparator | May 2024 → Nov 2025 | plasma cell myeloma | Celgene Corporation | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT06464991 Comparator | Mar 2024 → Aug 2027 expected | plasma cell myeloma | Nanjing IASO Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06152575 Comparator | Feb 2024 → Aug 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT05730036 Comparator | Sep 2023 → Apr 2033 expected | refractory plasma cell neoplasm | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 3 | NCT05675319 Comparator | Mar 2023 → Mar 2025 | plasma cell myeloma | University Medical Center Hamburg-Eppendorf | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05438043 Background | Dec 2022 → Jan 2029 expected | plasma cell myeloma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05405166 Background | Jun 2022 → Nov 2024 overdue | plasma cell myeloma | Sanofi | Active not recruiting | Met primary |
| Phase 3 | NCT05028348 Background | Apr 2022 → Mar 2026 overdue | plasma cell myeloma | European Myeloma Network B.V. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06956170 Background | Feb 2022 → May 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | Missed primary |
| Phase 3 | NCT05020236 Comparator | Oct 2021 → Apr 2026 overdue | plasma cell myeloma | Pfizer | Recruiting | No outcome recorded |
| Phase 3 | NCT04484623 Background | Oct 2020 → Jan 2024 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | Met primary |
| Phase 3 | NCT04162210 Comparator | Apr 2020 → Sep 2022 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | Missed primary |
| Phase 3 | NCT03539744 Comparator | Oct 2018 → Aug 2026 overdue | plasma cell myeloma | AbbVie | Active not recruiting | Missed primary |
| Phase 3 | NCT03143049 Background | Sep 2017 → Jun 2018 | — | National University Hospital, Singapore | Unknown | Met primary |
| Phase 3 | NCT03180736 Background | Jun 2017 → Jul 2020 | plasma cell myeloma | Stichting European Myeloma Network | Completed | Met primary |
| Phase 3 | NCT03151811 Comparator | Jun 2017 → Feb 2021 | plasma cell myeloma | Oncopeptides AB | Terminated | Met primary |
| Phase 3 | NCT02990338 Background | Dec 2016 → Nov 2018 | plasma cell myeloma | Sanofi | Completed | Met primary |
| Phase 3 | NCT02726581 Background | Aug 2016 → Mar 2022 | plasma cell myeloma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT02576977 Background | Oct 2015 → Jul 2018 | plasma cell myeloma | Merck Sharp & Dohme LLC | Terminated | Missed primary Stop: Business |
News releases announcing trial results or a regulatory action · 63
| Date | Issuer | Release |
|---|---|---|
| 2026-08-19 | Lotus Pharmaceutical | Regulatory Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan lotuspharm.com ↗
The approval marks another step in Lotus’s expansion in Japan, with pomalidomide becoming the Company’s second product to receive marketing approval in the country, following lenalidomide in 2023. |
| 2026-07-23 | Janssen Research & Development, LLC | Results TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma jnj.com ↗
The study demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival for both investigational arms compared with investigator’s choice standard of care. |
| 2026-07-23 | Janssen Research & Development, LLC | Results TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma jnj.com ↗ |
| 2026-07-10 | Sanofi | Results Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector sanofi.com ↗
The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd. |
| 2026-06-13 | Janssen Research & Development, LLC | Results New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma jnj.com ↗
Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months. |
| 2026-06-13 | Janssen Research & Development, LLC | Results New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma jnj.com ↗
TALVEY plus DARZALEX FASPRO with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months |
| 2026-05-26 | GlaxoSmithKline | Results GSK to showcase long-term outcomes and pipeline expansion with latest oncology research at ASCO and EHA gsk.com ↗
DREAMM-8 long-term responder and sustained minimal residual disease negativity analyses will show depth and durability of response for patients treated with belantamab mafodotin in combination with pomalidomide and dexamethasone in RRMM (ASCO abstract #7565 and rapid oral presentation abstract #7515). |
| 2025-12-07 | CellCentric Ltd. | Results CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting cellcentric.com ↗
Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients |
| 2025-12-02 | AbbVie | Results AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers abbvie.com ↗
Preliminary data from the dose escalation portion of the study (n=82) highlight that etentamig in combination with POM+DEX achieved an ORR of 81% and a very good partial response or better (≥VGPR) of 72% at median follow-up of 23 months (range: 1-33 months). |
| 2025-11-03 | Hoffmann-La Roche | Results Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 roche.com ↗
Clinical and exploratory biomarker analysis from the phase Ib CAMMA-1 study shows investigational cevostamab in combination with pomalidomide and dexamethasone induces high ORR, very good partial response (VGPR) or better rates, and durable remissions, in R/R multiple myeloma. |
| 2025-11-03 | Genentech, Inc. | Results Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 gene.com ↗
Clinical and exploratory biomarker analysis from the Phase Ib CAMMA-1 study shows investigational cevostamab in combination with pomalidomide and dexamethasone induces high ORR, very good partial response or better rates, and durable remissions, in R/R multiple myeloma. |
| 2025-11-03 | CellCentric Ltd. | Results CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting cellcentric.com ↗
Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety profile in a heavily pretreated population |
| 2025-07-24 | GlaxoSmithKline | Regulatory Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma gsk.com ↗ |
| 2025-06-03 | Sanofi | Results Press Release: ASCO: new Sarclisa data support subcutaneous administration with on-body injector sanofi.com ↗
Objective response rate (ORR) with Sarclisa SC-Pd was 71.1% compared to 70.5% with Sarclisa IV-Pd, establishing non-inferiority (risk ratio [RR] 1.008; 95% confidence interval [CI]: 0.903-1.126; p=0.0006). |
| 2025-01-09 | Sanofi | Results Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma sanofi.com ↗
Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV |
| 2024-12-10 | CellCentric Ltd. | Results CellCentic Presents Latest Clinical Data at ASH: Promising Efficacy and Safety in Multiple Myeloma cellcentric.com ↗
The data shared at ASH highlights the encouraging efficacy and manageable safety profile of inobrodib in combination with pomalidomide and dexamethasone in heavily pre-treated RRMM patients, including those who have failed multiple prior treatments. |
| 2024-12-09 | Sanofi | Results Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients sanofi.com ↗
Results showed the addition of Sarclisa to pomalidomide, and dexamethasone (Pd) resulted in rapid hematological responses in patients with relapsed AL amyloidosis, who experienced suboptimal response to previous therapy or at relapse. |
| 2024-11-25 | GlaxoSmithKline | Regulatory Blenrep combinations accepted for review by the US FDA for the treatment of relapsed/refractory multiple myeloma gsk.com ↗
The US FDA has assigned a Prescription Drug User Fee Act action date of 23 July 2025. |
| 2024-09-27 | Janssen Research & Development, LLC | Results TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma jnj.com ↗
RIO DE JANEIRO (September 27, 2024)– Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY®(talquetamab-tgvs) with DARZALEXFASPRO®(daratumumab and hyaluronidase-fihj) and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response rate (ORR) of 82 percent, further supporting the investigation of this combination. |
| 2024-09-27 | Janssen Research & Development, LLC | Results TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma jnj.com ↗ |
| 2024-06-17 | Ascentage Pharma Group Inc. | Results Live from EHA 2024 | Ascentage Pharma Releases Updated Data of Lisaftoclax in Patients with R/R MM and AL Amyloidosis Highlighting Marked Improvement in ORR ascentage.com ↗
From the primary analysis, it demonstrated that lisaftoclax + pomalidomide in R/R MM could achieve ≥very good partial response (VGPR) rate of 33.3%, and higher VGPR along with increasing lisaftoclax dosage. |
| 2024-06-14 | Janssen Research & Development, LLC | Results TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma jnj.com ↗
Longer follow-up from the Phase 1b MonumenTAL-2 study of the investigational use of TALVEY®and pomalidomide show deep responses and a manageable safety profile in patients with RRMM and support the potential to combine TALVEY®with an immunomodulatory agent (IMiD). |
| 2024-06-14 | Janssen Research & Development, LLC | Results TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma jnj.com ↗
Longer follow-up from the Phase 1b MonumenTAL-2 study of the investigational use of TALVEY® and pomalidomide show deep responses and a manageable safety profile in patients with RRMM and support the potential to combine TALVEY ® with an immunomodulatory agent (IMiD). |
| 2024-06-02 | GlaxoSmithKline | Results Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma gsk.com ↗
On the primary endpoint of progression-free survival (PFS), a statistically significant and clinically meaningful improvement (hazard ratio [HR]: 0.52 [95% confidence interval (CI): 0.37-0.73], p-value<0.001) was observed with the belantamab mafodotin combination (n=155) compared to the bortezomib combination (n=147). |
| 2024-03-07 | GlaxoSmithKline | Results GSK announces positive results from DREAMM-8 phase III trial for Blenrep versus standard of care combination in relapsed/refractory multiple myeloma gsk.com ↗
The trial met its primary endpoint of progression-free survival (PFS) at a pre-specified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee (IDMC). |
| 2023-12-11 | Janssen Research & Development, LLC | Results Treatment with CARVYKTI® (ciltacabtagene autoleucel) Resulted in Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Disease-Specific Symptoms in Patients with Earlier-Line Multiple Myeloma jnj.com ↗ |
| 2023-12-11 | Janssen Research & Development, LLC | Results New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma jnj.com ↗
Results from the Phase 1b MonumenTAL-2 study of TALVEY™ and pomalidomide for the treatment of patients with RRMM highlight the potential to combine TALVEY™ with other anti-myeloma therapies. |
| 2023-12-11 | Janssen Research & Development, LLC | Results New Analyses Demonstrate Versatility and Continued Efficacy of TALVEY™ in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma jnj.com ↗
Results from the Phase 1b MonumenTAL-2 study of TALVEY™ and pomalidomide for the treatment of patients with RRMM highlight the potential to combine TALVEY™ with other anti-myeloma therapies. |
| 2023-12-11 | CellCentric Ltd. | Results CellCentric discloses significant new clinical data, demonstrating inobrodib’s efficacy in ongoing Phase I/IIa clinical trials cellcentric.com ↗
As now shown clinically, patients refractory to pomalidomide become responsive to inobrodib combined with pom + dex. |
| 2023-09-29 | AbbVie | Results AbbVie Presents Results from Phase 3 CANOVA Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma abbvie.com ↗
Patients receiving VenDex showed improvement in median PFS of 9.9 months compared to 5.8 months with the combination of study comparator pomalidomide and dexamethasone (PomDex); however, the results did not reach statistical significance [HR = 0.823, 95% CI: (0.596, 1.136); p-value of 0.237]. |
| 2023-06-09 | Lotus Pharmaceutical | Regulatory Lotus Reported Unaudited May Consolidated Revenues of NT$1,322 million, with 51.8% growth YoY lotuspharm.com ↗
Excitingly, Lotus has received its first approval from Canadian health authorities for pomalidomide, a generic version of Pomalyst®. |
| 2022-12-11 | CellCentric Ltd. | Results CellCentric presents early haem clinical data at ASH cellcentric.com ↗
Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear responses seen in first cycle of dosing |
| 2022-11-07 | GlaxoSmithKline | Results GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma gsk.com ↗
The observed median progression-free survival was longer for belantamab mafodotin vs PomDex (11.2 months vs 7 months). |
| 2021-12-13 | GlaxoSmithKline | Results New data presented at ASH 2021 highlight potential of Blenrep (belantamab mafodotin-blmf) in combination with standard of care therapies in earlier lines of multiple myeloma treatment gsk.com ↗
Across all dosing cohorts (n=54), belantamab mafodotin plus PomDex resulted in an ORR of 88.9%, with 72.2% achieving a VGPR or better and a median progression-free survival (mPFS) of 17 months (95% CI, 14.5-not yet reached). |
| 2021-07-12 | Janssen Research & Development, LLC | Regulatory Janssen Announces U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse jnj.com ↗
DARZALEX FASPRO® is now the first and only subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone |
| 2021-06-22 | Janssen Research & Development, LLC | Regulatory DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma jnj.com ↗
Daratumumab SC is also now the first subcutaneous anti-CD38 monoclonal antibody approved in combination with pomalidomide and dexamethasone in pre-treated multiple myeloma |
| 2021-05-19 | Karyopharm Therapeutics Inc | Results Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the 2021 American Society of Clinical Oncology Annual Meeting karyopharm.com ↗
Once-weekly selinexor was shown in this Phase 1b /2 study to be safely combined with Pomalyst® (pomalidomide) and low-dose dexamethasone (XPd) in patients with heavily pretreated MM. |
| 2020-12-07 | Karyopharm Therapeutics Inc | Results Karyopharm Presents XPOVIO® (Selinexor) Data in Multiple Myeloma and Diffuse Large-B-Cell Lymphoma at the American Society of Hematology 2020 Annual Meeting karyopharm.com ↗
The highlights of our ASH data this year include updated data from multiple arms of the STOMP study where once weekly oral XPOVIO continues to demonstrate compelling and durable responses in important patient subgroups when combined with approved multiple myeloma therapies. |
| 2020-12-04 | Janssen Research & Development, LLC | Results Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Regimen After First or Subsequent Relapse in Multiple Myeloma jnj.com ↗
The APOLLO study represents the ninth positive Phase 3 study for daratumumab. |
| 2020-11-12 | Halozyme Therapeutics | Regulatory Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalidomide And Dexamethasone For Patients With Relapsed Or Refractory Multiple Myeloma halozyme.com ↗
The applications seek approval of the combination of DARZALEX FASPRO™/ DARZALEX® SC with pomalidomide and dexamethasone (D-Pd) for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. |
| 2020-05-15 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma bms.com ↗ |
| 2020-03-02 | Sanofi | Regulatory Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma sanofi.com ↗
The U.S. Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. |
| 2019-12-07 | Karyopharm Therapeutics Inc | Results Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting karyopharm.com ↗
patients with Pomalyst-naïve and Revlimid® (lenalidomide)-relapsed or -refractory myeloma achieved a 56% overall response rate (ORR) and a 12-month progression free survival (PFS) |
| 2019-11-06 | Karyopharm Therapeutics Inc | Results Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting karyopharm.com ↗
In both arms the response rates and safety profile remain highly encouraging. |
| 2019-08-27 | Bristol-Myers Squibb | Regulatory European Commission Approves Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone (EPd) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma bms.com ↗
We are proud that the European Commission has again recognized the role of Empliciti in helping European patients with multiple myeloma by approving a second Empliciti- based regimen in the relapsed and refractory setting. |
| 2019-07-26 | Bristol-Myers Squibb | Regulatory Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone for Treatment of Patients with Relapsed and Refractory Multiple Myeloma bms.com ↗
The CHMP recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. |
| 2019-06-14 | Bristol-Myers Squibb | Results Bristol-Myers Squibb Presents Updated Efficacy Data from Phase 2 Trial of Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) bms.com ↗
Treatment with EPd was associated with a 46% reduction in risk of death [Hazard Ratio (HR) 0.54; 95% Confidence Interval (CI): 0.30 to 0.96] versus treatment with Pd alone. |
| 2019-06-14 | Karyopharm Therapeutics Inc | Results Karyopharm Reports New and Updated Selinexor Combination Data from the Phase 1b/2 STOMP Study at the European Hematology Association 2019 Annual Meeting karyopharm.com ↗
Additionally, the Darzalex and Pomalyst arms of the STOMP study continue to demonstrate impressive response rates, including encouraging rates of very good partial responses (VGPR), which indicate a 90% or greater reduction in a patient’s disease burden. |
| 2018-11-29 | Bristol-Myers Squibb | Results Bristol-Myers Squibb to Highlight New Data from Broad Oncology Portfolio at the 60th American Society of Hematology Annual Meeting bms.com ↗
First disclosure of results from a Phase 2 trial supports safety and efficacy of Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone in relapsed/refractory (R/R) multiple myeloma |
| 2018-11-06 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Approves Empliciti® (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma bms.com ↗ |
| 2018-09-18 | Bristol-Myers Squibb | Regulatory European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma bms.com ↗
Validation of the application confirms the submission is complete and begins the EMA’s centralized review process. |
| 2018-08-23 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma bms.com ↗
The FDA granted the application priority review with an action date of December 27, 2018. |
| 2018-06-17 | Bristol-Myers Squibb | Results Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone Reduces the Risk of Disease Progression by 46% Versus Pomalidomide/Dexamethasone Alone in Patients with Relapsed or Refractory Multiple Myeloma bms.com ↗ |
| 2018-06-01 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma bms.com ↗
FDA action removes partial hold on CheckMate -602, the last of holds previously placed on three Opdivo-based combination trials in relapsed or refractory multiple myeloma |
| 2017-12-05 | Bristol-Myers Squibb | Regulatory U.S. Food and Drug Administration Lifts Partial Clinical Holds on Two Opdivo-based Combination Studies in Multiple Myeloma bms.com ↗ |
| 2017-09-07 | AstraZeneca | Regulatory Celgene and AstraZeneca provide update on the FUSION clinical trial programme astrazeneca.com ↗
The FDA has taken similar action with other combination trials in patients with multiple myeloma. |
| 2017-09-06 | Bristol-Myers Squibb | Regulatory Bristol-Myers Squibb Provides an Update on Three Opdivo-based Combination Clinical Studies in Multiple Myeloma bms.com ↗
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on CA209602 (CheckMate-602), CA209039 (CheckMate-039) and CA204142, three clinical trials investigating Opdivo (nivolumab)-based combinations in patients with relapsed or refractory multiple myeloma. |
| 2017-07-05 | Merck Sharp & Dohme LLC | Regulatory Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating KEYTRUDA® (pembrolizumab) in Combination with Pomalidomide or Lenalidomide merck.com ↗
The FDA has determined that the data available at the present time indicate that the risks of KEYTRUDA plus pomalidomide or lenalidomide outweigh any potential benefit for patients with multiple myeloma. |
| 2017-06-12 | Merck Sharp & Dohme LLC | Results Merck Provides Update on Multiple Myeloma Studies KEYNOTE-183 and 185 of KEYTRUDA® (pembrolizumab) in Combination with Other Therapies merck.com ↗
Merck has accepted the external Data Monitoring Committee recommendation to pause new enrollment on KEYNOTE-183 and KEYNOTE-185, two studies exploring KEYTRUDA treatment in combination with other therapies in multiple myeloma. |
| 2016-12-05 | Karyopharm Therapeutics Inc | Results Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting karyopharm.com ↗
Other key presentations at the meeting described clinical data demonstrating the activity of selinexor in combination with carfilzomib (Kyprolis®) and pomalidomide (Pomalyst®) in MM, as well as selinexor with dexamethasone in quad- and penta-refractory MM in the STORM trial. |
| 2016-06-10 | Karyopharm Therapeutics Inc | Results Karyopharm Presents Preliminary STOMP Phase 1b Clinical Data at 2016 European Hematology Association Annual Meeting karyopharm.com ↗
We are highly encouraged by the promising, durable activity and safety we continue to observe in the STOMP trial, |
| 2016-05-19 | Karyopharm Therapeutics Inc | Results Karyopharm to Present Preliminary STOMP Phase 1B Clinical Data at 2016 European Hematology Association Annual Meeting karyopharm.com ↗
These clinical data further support the synergistic activity of selinexor in combination with proteasome inhibitors and immunomodulatory agents, or iMiDs, which was previously demonstrated in preclinical models of multiple myeloma. |
| 2014-11-24 | AbbVie | Results ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition abbvie.com ↗
SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide. |
All press releases naming this drug 68 releases
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 297 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pomalidomide | “Patients will receive APG-2575 at target dose once daily for 28 days plus pomalidomide (4 mg ) on Days 1 through 21 and dexamethasone (40 mg for patients ≤ 75 years old or 20...” NCT04942067 ↗284“Patient eligible to enter the study will receive 9 to 12 cycles (according to response) of intravenous Isatuximab (10 mg/kg) and oral Pomalidomide 4 mg from day 1 to day 21 and...” NCT05066607 ↗ “The proposed study is an open-label, single-arm, Phase-Ib/II trial to assess the efficacy of oral drug combination ruxolitinib and pomalidomide in primary and secondary MF patients.” NCT01644110 ↗ “the investigator will decide to continue treatment with Rituximab one more cycle combined with Temozolomide, Pomalidomide, or Lenalidomide, etc., until CSF-ctDNA turns negative.” NCT06594432 ↗ “Combination regimen for hematological malignancy Lenalidomide: 25 mg on Days 1 to 21 of each 28-day cycle; or Pomalidomide: 4 mg on Days 1 to 21 of each 28-day cycle” NCT05828459 ↗ “Pomalidomide (alone or in combination with dexamethasone) has been approved by the United States Food and Drug Administration (FDA) for the treatment of MM patients” NCT02188368 ↗ “Given that pomalidomide is an FDA approved drug for patients with relapsed or progressive myeloma” NCT01889420 ↗ “Pomalidomide 4mg per tablet 4mg orally from Days 1 to 7 of each cycle” NCT07072208 ↗ “Pomalidomide, orally, at 4 mg on Days 1- 21 of each 28-day cycle.” NCT03215524 ↗ “Pomalidomide: 4mg/day oral route on 21 days per cycle” NCT02244125 ↗ “DTRM-555 (DTRMWXHS-12, everolimus and pomalidomide)” NCT04305444 ↗ |
| Known as | Actimid | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | CC-4047 | “The purpose of the study is to determine the safety and efficacy of single agent CC-4047 (pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are...” NCT00717522 ↗14“A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV” NCT01495598 ↗ “A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects” NCT01986894 ↗ “Pomalidomide (CC-4047) is a drug given by mouth, which can change or regulate the functioning of the immune system.” NCT01570387 ↗ “Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance” NCT01745588 ↗ “Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone” NCT02045017 ↗ “pomalidomide (CC-4047)” NCT02659930 ↗ “Pomalidomide (CC-4047)” NCT01559129 ↗ “pomalidomide (CC-4047” NCT01135199 ↗ |
| Known as | IMID 3 | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Imnovid | “Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle” NCT05651932 ↗1“Imnovid (pomalidomide)” NCT02046915 ↗ |
| Known as | Imnovid (previously pomalidomide celgene) | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | POM | “This phase 1b study (NCT02431208) evaluated the safety and efficacy of the anti-programmed death-ligand 1 monoclonal antibody atezolizumab (Atezo) alone or in combination with...” PMID 37559718 ↗ Jul 20235“We therefore conducted a phase I/II study to establish the safety and preliminary efficacy of IXA with pomalidomide (POM) and dexamethasone (DEX) in lenalidomide (LEN)/PI-refractory MM.” PMID 34559902 ↗ Oct 2021 “We conducted a prospective phase 2 study investigating the safety and efficacy of pomalidomide (POM) in children and young adults with recurrent and progressive primary brain tumors.” PMID 34168987 ↗ Jun 2021 “This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A)” NCT01946477 ↗ “Daratumumab (DARA) in combination with pomalidomide (POM) and low-dose dexamethasone (dex) (DPd)” NCT03651128 ↗ “pomalidomide (POM) plus low-dose dexamethasone (POM + LoDEX)” PMID 26149712 ↗ Jun 2015 |
| Known as | Pomalidomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide (POM) | “Pomalidomide (POM)” NCT01575925 ↗ |
| Known as | Pomalidomide (Pomalyst, Imnovid) | “Pomalidomide (Pomalyst, Imnovid)” NCT05651932 ↗ |
| Known as | Pomalidomide accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide krka | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide viatris | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide zentiva | ChEMBL registry synonym — accepted as the source's own label CHEMBL43452 ↗ |
| Known as | Pomalidomide( Anyue, Chia Tai TIANQING, China) | “Pomalidomide( Anyue®, Chia Tai TIANQING, China)” NCT04762745 ↗ |
| Known as | Pomalyst | “The study drug, pomalidomide (POMALYST®), has been approved by the United States Food and Drug Administration (FDA) to treat patients with multiple myeloma (MM).” NCT01835561 ↗2“Drug: Pomalidomide (Pomalyst, Imnovid): Orally, for 21 days in each 28-day cycle” NCT05651932 ↗ “pomalidomide (also known as Pomalyst)” NCT01745588 ↗ |
| Action | Inhibit | “in vitro suppression of TNF-α production” NCT00770757 ↗ |
| Modality | Other / unclassified | “Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects.” PMID 26160879 ↗ Jul 2015 |
| Route | Oral | “Participants received 2 mg oral pomalidomide daily” NCT00463385 ↗ |
| Target | TNF | “in vitro suppression of TNF-α production” NCT00770757 ↗ |